

PROGRAM

7th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 24-27, 2017

Chairmen: **F. Lo Coco, M.A. Sanz**
Honorary President: **F. Mandelli**



7th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 24-27, 2017

Dear Colleague,

we kindly remind you that the 7th International Symposium on Actue Promyelocytic Leukemia will be held in Rome on September 24-27, 2017 (www.apl2017.com).

As you can see from the website, this conference has long since become a traditional, well established meeting that gathers togheter renowned scientist, researchers and clinicals from all over the globe. In fact, basic science, translational and clinical experts will update the audience on most recent advances related to both laboratory and clinical research in APL and related fields (differentiation treatments, targeted therapy, oncogenic signaling, minimal residual disease etc.).

In addition to clinical and research update on unpublished work, there will be an educational session to address the issues related to diagnostics and management of the disease. Furthermore, this symposium will host a forum on international collaboration and projects for implementing clinical networking on APL and available treatment resources in developing countries.

Finally, the symposium offers a great opportunity for young investigators interested in the field to present their work in dedicated oral and poster session.

Please remember that the deadline for abstract submission is June 16, 2017.

We look forward to welcoming you to the Eternal City!

Francesco Lo Coco
Symposium co-chairmen

Miguel A. Sanz
Symposium co-chairmen

FACULTY

Oussama	Abla	Toronto, Canada	Junmin	Li	Shanghai, China
Lionel	Adès	Paris, France	Francesco	Lo Coco	Rome, Italy
Myriam	Alcalay	Milan, Italy	Franco	Locatelli	Rome, Italy
Sergio	Amadori	Rome, Italy	Bob	Lowenberg	Rotterdam, The Netherlands
William	Arcese	Rome, Italy	David	Martinez-Cuadron	Valencia, Spain
Giuseppe	Avvisati	Rome, Italy	Vikram	Mathews	Vellore, India
Nancy	Berliner	Boston, USA	Wilson H.	Miller	Montreal, Canada
Massimo	Brescia	Rome, Italy	Saverio	Minucci	Milan, Italy
Mammen	Chandy	Kolkata, India	Pau	Montesinos	Valencia, Spain
Zhu	Chen	Shanghai, China	Clara	Nervi	Rome, Italy
Laura	Cicconi	Rome, Italy	Fabrizio	Pane	Naples, Italy
Hughes	de Thé	Paris, France	Pier Giuseppe	Pelicci	Milan, Italy
Laurent	Degos	Paris, France	Uwe	Platzbecker	Dresden, Germany
Fabio	Efficace	Rome, Italy	Eduardo	Rego	Sao Paulo, Brazil
Elihu	Estey	Seattle, USA	Nigel	Russell	Nottingham, United Kingdom
Anna	Falanga	Bergamo, Italy	Guillermo	Sanz	Valencia, Spain
Brunangelo	Falini	Perugia, Italy	Miguel A.	Sanz	Valencia, Spain
Pierre	Fenaux	Paris, France	Jaime	Sanz Caballer	Valencia, Spain
Felicetto	Ferrara	Naples, Italy	Matthew	Seftel	Winnipeg, Canada
Francesco	Grignani	Perugia, Italy	Jorge	Sierra	Barcelona, Spain
Syed Khizer	Hasan	Mumbai, India	Akihiro	Takeshita	Nagoya, Japan
Harry	Iland	Camperdown, Australia	Martin S.	Tallman	New York, USA
Anand	Jillella	Atlanta, USA	Anna M.	Testi	Rome, Italy
Richard	Larson	Chicago, USA	Christian	Thiede	Dresden, Germany
Soren	Lehmann	Uppsala, Sweden	Adriano	Venditti	Rome, Italy
Eva	Lengfelder	Mannheim, Germany	Maria Teresa	Voso	Rome, Italy
Giuseppe	Leone	Rome, Italy	Kankan	Wang	Shanghai, China

2.00 pm Registration

3.00 - 4.00 pm **Session I - Advances in diagnosis, classification and monitoring of AML**

CME

Chair: **F. Pane**

- New developments in molecular diagnosis of AML
- The new WHO classification of AML
- MRD in AML: current status and future perspectives

*C. Thiede
B. Falini
A. Venditti*

4.00 - 5.00 pm **Session II - Advances in diagnosis and treatment of myelodysplastic syndromes**

CME

Chair: **E. Estey**

- Somatic mutations in diagnosis and prognosis of MDS
- Treatment of low-risk MDS
- Treatment of high-risk MDS and AML

*M.T. Voso
U. Platzbecker
G. Sanz*

5.00 - 6.00 pm **Session III - Advances in targeted therapy of AML**

CME

Chair: **F. Ferrara**

- FLT3 inhibitors
- Other molecular targets
- Antibody-driven therapy

*J. Sierra
R.A. Larson
S. Amadori*

6.00 - 6.20 pm **Opening ceremony**

CME

6.20 - 7.10 pm **KEYNOTE LECTURE**

Introducer: **H. de Thé**

Translational Research on the Curative Therapy for Acute Promyelocytic Leukemia

Z. Chen

7.10 - 8.30 pm *Welcome cocktail*

8.30 - 9.30 am **Educational Session - Biology, diagnosis and management of APL**

CME

Chairs: **M. Alcalay, M.A. Sanz**

- Pathogenesis, diagnosis and monitoring
- Front-line therapy
- Therapy of relapse

L. Cicconi
P. Montesinos
L. Adès

9.30 - 10.20 am **Session V - Molecular bases of targeted therapy and resistance**

CME

Chair: **F. Grignani**

- Regulation of self renewal in cancer stem cells
- Novel insights into the basis for APL pathogenesis and therapy resistance

P.G. Pelicci
H. de Thé

CO001

THE RARA INTERACTOME: THE S100 CALCIUM BINDING PROTEIN A3 BINDS DIRECTLY AND SPECIFICALLY TO RARA AND PML-RAR AND MODULATE THEIR ACTIVITY IN ACUTE PROMYELOCYTIC CELLS

Gianni M., Terao M., Brunelli L., Borleri G., Garattini E. (Milan, Bergamo - Italy)

10.20 - 10.50 am *Coffee break*

10.50 - 11.30 pm **Session VI - Genome and epigenome of APL**

CME

Chairs: **L. Degos, P.G. Pelicci**

- Genomic and transcriptomic landscapes of Acute Promyelocytic Leukemia
- Mechanisms of response and resistance to epigenetic therapies

K. Wang
W.H. Miller

11.30 - 12.30 pm **Oral Session I - APL biology I**

CME

Chairs: **S. Minucci, C. Nervi**

CO002

WHOLE EXOME ANALYSIS OF RELAPSING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Bally C., Lehmann-Che J., Cassinat B., Ades L., Letouze E., Hirsch P., Mozziconacci M.J, Raynaud S., Delabesse E., Uzunov M., Hunault M., Lippert E., Lapillonne H., Ferrand C., Gervais C., Gachard N., Guerci A., Fenaux P., de Thé H. (Paris, Marseille, Nice, Toulouse, Angers, Pessac, Besançon, Strasbourg - Mulhouse, Limoges, Vandoeuvre - France)

CO003

PML AND RARA MUTATIONS IN REFRACTORY ACUTE PROMYELOCYTIC LEUKAEMIA

Iaccarino L., Ottone T., Alfonso V., Divona M., Cicconi L., Bocchia M., Cairoli R., Voso M.T., Lo Coco F. (Rome, Siena, Milan - Italy)

CO004 ARSENIC OVERCOMES RA-RESISTANCE CONFERRED BY FLT3-ITD IN A MOUSE MODEL OF APL
Rahmé R., Esnault C., de Thé H. (Paris - France)

CO005 MOLECULAR ANALYSIS OF THE INTERPLAY BETWEEN ALL-TRANS RETINOIC ACID AND HISTONE DEACETYLASE INHIBITORS IN ACUTE PROMYELOCYTIC LEUKEMIA CELLS
Mahendrarajah N., Noack K., Hennig D., Mahboobi S., Heinzl T., Krämer O.H. (Mainz, Jena, Regensburg - Germany, Odense - Denmark)

CO006 MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA ARE SIMILAR AT DIAGNOSIS AND RELAPSE AND ETV6 MAY BE A MOLECULAR BIOMARKER OF DECREASED DISEASE-FREE SURVIVAL AND HIGH-RISK DISEASE INDEPENDENT OF WHITE BLOOD CELL COUNT
Stein E.M., Viny A.D., Devlin S., Paietta E.M., Racevskis J., Gallagher R., Lancet J.E., Powell B.L., Appelbaum F.R., Larson R.A., Wiernik P., Rowe J.M., Levine R.L., Tallman M.S. (New York, Winston-Salem, Tampa, Seattle, Chicago - USA, Jerusalem - Israel)

CO007 ACUTE PROMYELOCYTIC LEUKEMIA (APL): MOLECULAR CHARACTERIZATION BY CANCER IMMUNE PROFILING MAY IDENTIFY PATIENTS AT RISK OF EARLY DEATH
Kolhe R., Pundkar C., Savage N., Mondal A., Jillella A., Kota V. (Augusta, Atlanta - USA)

12.30 - 1.50 pm Lunch

1.50 - 3.10 pm

CME

Session VII - Early death and population-based studies

Chairs: **B. Löwenberg, E. Rego**

- Observational studies in APL: what have we learned and what can we still learn? *M. Seftel*
- Early deaths as the most significant threat to APL patients in real life *S. Lehmann*
- Reproducing clinical trial results in the "REAL WORLD". The Georgia and South Carolina (USA) APL experience *A. Jillella*

CO008 EARLY DEATH AND OUTCOMES OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA USING ARSENIC AND RETINOIC ACID AS FIRST-LINE TREATMENT: A REAL WORLD STUDY
Zhu H.H., Jiang B., Jiang Q., Jiang H., Lu J., Huang X.J. (Beijing - China)

CO009 TREATMENT CENTER CHARACTERISTICS CORRELATED TO EARLY DEATH RATES IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: ANALYSIS OF THE U.S. SEER DATA
Park J.H., Devlin S., Hsu M., Lynch C., Schwartz A., Gonsalves L., Green M., Li C., Stroup N., Douer D., Tallman M.S. (New York - USA)

3.10 - 4.10 pm

CME

Session VIII - Management of APL in developing countries I

Chairs: **N. Berliner, P. Fenaux**

- Long term follow up of the International Consortium on Acute Promyelocytic Leukemia: achievements and limitations
- Progress and constraints in treating APL in India

*E. Rego
M. Chandy*

CO010 EPIDEMIOLOGY, DIAGNOSIS, CLINICAL FEATURES AND OUTCOME OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED AT BATNA AGAINST CANCER CENTER IN ALGERIA

Saidi M., Soltani F., Aiche M., Merrouche M., Kacha F., Refis S., Nacib R., Hariz A., Zeroual N., Rechache H., Belaid D., Gareh B., Temlali M., Dridi R., Bouaziz S., Bekache A. (Batna - Algeria)

CO011 PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN LATIN AMERICAN CHILDREN. IS IT POSSIBLE TO WORK TOGETHER? THE CLEHOP INITIATIVE

Freigeiro D., Antillon F., Moran L., Salgado C., Costa J., Garcia Guevara R., Cabrera García V., Lee M., Ribeiro R., Metzger M., Conter V., Testi A. (Grupo Argentino de Tratamiento de Leucemia Aguda (GATLA), Asociación HematoOncológica Pediátrica Centroamericana (AHOPCA), Programa Infantil de Drogas Antineoplásicas (PINDA) - Chile, San Salvador, San Paolo - Brazil, Sociedad Venezolana de Hematología - Venezuela, Veracruz - Mexico, Memphis - USA, Monza, Rome - Italy)

4.20 - 5.50 pm

Teva sponsored symposium

Next-generation APL leaders: Teva's award for young hematologists

Chair: **B. Löwenberg**

Welcome and introduction

B. Löwenberg

Arsenic, a targeted curative therapy of APL

H. de Thé

TO001 VERY ELDERLY ACUTE PROMYELOCYTIC LEUKEMIA: A MULTICENTRIC EXPERIENCE

O. Salamero (Barcelona, Spain)

TO002 PROTHROMBINASE COMPLEX ASSEMBLY AND IN SITU FIBRIN DEPOSITION ON THE SURFACE OF ACUTE PROMYELOCYTIC LEUKEMIA CELLS

X. Yang (Harbin, China)

TO003 OVERVIEW OF PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA IN A DEVELOPING COUNTRY

F. Andrade (Rio de Janeiro - Brazil)

TO004 COMBINING GENE MUTATION WITH GENE EXPRESSION DATA IMPROVES OUTCOMES PREDICTION IN ACUTE PROMYELOCYTIC LEUKEMIA

A.R. Lucena-Araujo (Recife, Brazil)

Conclusions

B. Löwenberg

8.40 - 9.30 pm

Oral Session II - APL biology II

Chairs: **S.K. Hasan, C. Thiede**

CME

- CO013 RETINOIC ACID AND ARSENIC TRIOXIDE SENSITIZE ACUTE PROMYELOCYTIC LEUKEMIA CELLS TO ER STRESS
Masciarelli S., Capuano E., Ottone T., Divona M., De Panfilis S., Noguera N.I., Lo Coco F., Fazi F. (Rome - Italy)
- CO014 PML/RARA INTERFERES WITH NRF2 FUNCTION IN ACUTE PROMYELOCYTIC LEUKEMIA CELLS
Noguera N.I., Catalano G., Travaglini S., Banella C., Voso M.T., Lo Coco F. (Rome - Italy)
- CO015 MOLECULAR ANALYSIS OF ACUTE PROMYELOCYTIC LEUKEMIA BY NEXT GENERATION SEQUENCING
Llop M., Gil J.V., Sargas C., Cervera J., Such E., Gil C., Sayas M.J., García R., Manso F., Fernández J.M., Martínez-Cuadrón D., Rodríguez R., Boluda B., Montesinos P., Sanz M.A., Barragán E. (Valencia, Alicante, Madrid - Spain, CIBERONC)
- CO016 METABOLIC CATASTROPHE OF ARSENIC TRIOXIDE RESISTANT CELLS IN ACUTE PROMYELOCYTIC LEUKEMIA
Balasundaram N., Ganesan S., Palani H.K., Alex A.A., David S., Balasubramanian P., Kulkarni U., George B., Mathews V. (Tamil Nadu - India)

CO017

CLINICAL SIGNIFICANCE OF COMPLEX KARYOTYPE AT DIGNOSIS IN PATIENTS WITH APL TREATED WITH ATRA AND CHEMOTHERAPY BASED PETHEMA TRIALS

Labrador J., Montesinos P., Bernal T., Vellenga E., Brunet S., González J., González M., Holowiecka A., Esteve J., Bergua J., González J.D., Gil C., Tormo M., Salamero O., Manso F., Milone G., de la Serna J., Moreno M.J., Pérez-Encinas M., Krsnik I., Ribera J.M., Cervera J., Calasanz M.J., Löwenberg B., Sanz M.A. (PETHEMA - Spain, HOVON - The Netherlands, PLAG - Poland, GATLA - Argentina)

9.30 - 11.00 am

Session IX - Update in frontline trials I

Chairs: **M. Seftel, M.S. Tallman**

CME

- Update of the Italian-German study APL0406 *G. Avvisati*
- Retinoic acid and arsenic trioxide with or without chemotherapy for acute promyelocytic leukemia with different risk stratifications: an interim analysis of China APL 2012 Study *J. Li*
- Recent results from the prospective studies on APL in the Japan Adult Leukemia Study Group (JALSG) *A. Takeshita*
- An update of APL 2006 trial results *P. Fenaux*
- Update on PETHEMA trials *M.A. Sanz*

11.00 - 11.20 am *Coffee break*

11.20 - 12.30 pm **Session X - Update in frontline trials II**

CME

Chairs: **M. Seftel, M. Tallman**

- The ALLG approach to incorporating arsenic trioxide: APML4 (final analysis) and APML5 (encapsulating therapy) *H. Iland*
- Potential for non conventional agents in upfront and relapsed APL *V. Mathews*
- Long term follow up of the NCRI AML17 trial of attenuated arsenic trioxide and ATRA therapy for newly diagnosed and relapsed acute promyelocytic leukaemia *N. Russell*
- Implications for AML clinical trials from experience with ATO + ATRA *E. Estey*

12.30 - 1.30 pm *Lunch*

1.30 - 2.30 pm **Session XI - The APL coagulopathy**

CME

Chairs: **G. Avvisati, M. Chandy**

- APL fatal bleeding and thrombosis in the ATRA era *A. Falanga*
- Thrombohemorrhagic disorders in APL: the unsolved issue *P. Montesinos*

CO018 DIFFERENTIAL EXPRESSION OF TISSUE FACTOR F3 AND NUCLEAR RECEPTORS 4A IN EARLY DEATH ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

Frech M., Stabla K., Nist A., Mernberger M., Teichler S., Brendel C., Altmann H., Platzbecker U., Thiede C., Stiewe T., Neubauer A. (Marburg, Dresden - Germany)

CO019 THE IMPACT OF ORAL ARSENIC AND ALL-TRANS-RETINOIC ACID ON COAGULOPATHY IN ACUTE PROMYELOCYTIC LEUKEMIA

Zhu H.H., Guo Z.P., Jiang J.S., Jiang Q., Jiang H., Huang X.J. (Beijing - China)

2.30 - 3.40 pm

CME

Session XII - APL in children and the elderly

Chairs: **R.A. Larson, F. Locatelli**

- Obesity and initial high white blood cell count are predictors of thrombo-hemorrhagic early deaths in children and adolescents with t(15;17) positive acute promyelocytic leukemia *O. Abl*
- Risk-adapted ATRA and chemotherapy in children with newly diagnosed acute promyelocytic leukemia: a 15-year multicentric experience *A. Testi*
- Characteristics and outcome of elderly APL patients treated with PETHEMA protocols *D. Martínez-Cuadrón*

CO020 TOXICITY IN PEDIATRIC PATIENTS TREATED WITH ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE INDUCTION: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP STUDY AAML1331
Kutny M., Alonzo T., Gerbing R., Wang Y., Fu C., Meshinchi S., Raimondi S., Hirsch B., Rajpurkar M., Abla O., Sung L., O'Dwyer K., Howell D., Sun W., Kahwash S., Kolb E., Feusner J., Gregory J. (Birmingham, Los Angeles, Seattle, Memphis, Minneapolis, Detroit, Rochester, Houston, Duarte, Columbus, Wilmington, Oakland, Morristown - USA, Toronto - Canada)

3.40 - 4.30 pm

Oral Session III - APL in children and elderlyChairs: **H. Iland, N. Russell**

CME

CO021 OUTCOME OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS EXPERIENCE OF CHILDREN WELFARE TEACHING HOSPITAL (2010-2015)
Al-Hadad S., Al-Jadiry M. (Baghdad - Iraq)

CO022 ORAL ARSENIC AND RETINOIC ACID FOR CHILDREN WITH LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA
Zhu H.H., Qin Y.Z. (Beijing - China)

CO023 ARSENIC TRIOXIDE CONSOLIDATION RESULTS IN EXCELLENT SURVIVAL IN YOUNG CHILDREN AS WELL AS OLDER CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP STUDY AAML0631
Kutny M., Alonzo T., Gerbing R., Wang Y., Fu C., Meshinchi S., Raimondi S., Hirsch B., Gamis A., Feusner J., Gregory J. (Birmingham, Los Angeles, Seattle, Memphis, Minneapolis, Kansas City, Oakland, Morristown - USA)

CO024 ARSENIC TRIOXIDE (ATO) AND ATRA WITH LIMITED CHEMOTHERAPY (CT) IN NEWLY DIAGNOSED STANDARD RISK APL IN THE ELDERLY. A REPORT BY THE FRENCH BELGIAN SWISS APL GROUP (APL 2006 TRIAL)
Ades L., Thomas X., Guerci A., Pigneux A., Vey N., Raffoux E., Castaigne S., Spertini O., Bron D., Marolleau J.P., Damaj G., Bordessoule D., Lejeune J., Chevret S., Fenaux P. (French Belgian Swiss APL Group)

CO025 COMPARING ARSENIC TRIOXIDE AND INDIGO NATURALIS FORMULA IN PEDIATRIC PATIENTS WITH ACUTE PROMYELOID LEUKEMIA: AN INTERIM REPORT OF MUTICENTER AND RANDOMIZED CLINICAL TRIAL SCCLG-APL
Luo X.Q., Cao L.Z., Wan W.Q., Lin Y.D., Fang J.P., Yang L.H., Li C.G., Chen H.Q., Chen G.H., Feng X.Q., Liu R.Y. (Changsha, Guangzhou, Shenzhen, Huizhou - China)

4.30 - 5.30 pm

Oral Session IV - Clinical studies and prognostic factorsChairs: **L. Degos, S. Lehmann**

CME

CO026 COMPARISON OF INDUCTION THERAPY IN ACUTE PROMYELOCYTIC LEUKEMIA WITH ARSENIC TRIOXIDE ALONE OR IN COMBINATION WITH ATRA
Ghavamzadeh A., Alimoghaddam K., Jalili M., Rostami S., Ghaffari S.H., Mousavi S.A., Bahar B., Jahani M. (Tehran - Iran)

CO027 FRONTLINE THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA: RANDOMIZED COMPARISON OF ATRA AND INTENSIFIED CHEMOTHERAPY INCLUDING HIGH DOSE CYTOSINE-ARABINOSIDE VERSUS ATRA AND ANTHRACYCLINES - A PROSPECTIVE MULTI CENTER RANDOMIZED CLINICAL TRIAL
Lengfelder E., Görlich D., Nowak D., Spiekermann K., Haferlach C., Krug U., Kreuzer K.A., Braess J., Schliemann C., Lindemann H.W., Horst H., Schiel X., Flasshove M., Hecht A., Schnittger S., Schneider S., Wörmann B., Hofmann W.K., Berdel W., Bormann E., Sauerland C., Büchner T., Hiddemann W., for the German Acute Myeloid Leukemia Cooperative Group (AMLCG) (Mannheim, Münster, Munich, Cologne, Regensburg, Hagen, Kiel, Düren, Berlin - Germany)

CO028 LONG-TERM OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS-RETINOIC ACID, ARSENIC TRIOXIDE AND GEMTUZUMAB OZOGAMICIN
Ravandi F., Abaza Y., Garcia-Manero G., Estey E., Borthakur G., Jabbour E., Faderl S., O'Brien S., Wierda W., Pierce S., Brandt M., McCue D., Luthra R., Patel K., Kornblau S., Kadia T., Daver N., DiNardo C., Jain N., Verstovsek S., Ferrajoli A., Andreeff M., Konopleva M., Estrov Z., Foudray M., McCue D., Cortes J., Kantarjian H. (Houston, Seattle, Hackensack, Irvine - USA)

CO029 ORAL ARSENIC AND RETINOIC ACID FOR HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA
Zhu H.H., Qin Y.Z., Huang X.J. (Beijing - China)

CO030 CLINICAL SIGNIFICANCE OF CD56 EXPRESSION IN PATIENTS WITH DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH THE PETHEMA LPA96, LPA99 AND LPA2005 PROTOCOLS: AN UPDATED ANALYSIS
Boluda B., Montesinos P., Bernal T., Vellenga E., Brunet S., González J., González M., Holowiecka A., Esteve J., Bergua J., González J.D., Gil C., Tormo M., Salamero O., Manso F., Milone G., de la Serna J., Moreno M.J., Pérez-Encinas M., Krsnik I., Ribera J.M., Escoda L., Löwenberg B., Sanz M.A. (PETHEMA - Spain, HOVON - The Netherlands, PLAG - Poland, GATLA - Argentina)

CO031 CHARACTERISTIC AND CLINICAL OUTCOME OF PATIENTS WITH APL AND INCREASED BODY MASS INDEX TREATED WITH THE PETHEMA PROTOCOLS

Rodriguez-Veiga R., Montesinos P., Vellenga E., Holowiecka A., De la Serna J., Bernal T., Gil C., Brunet S., Bergua J., González J., Ribera J.M., Tormo M., González M., Milone S., Benavente C., González J.D., Esteve J., Pérez-Encinas M., Salamero O., Manso F., Löwenberg B., Sanz M.A. (PETHEMA - Spain, PALG - Poland, HOVON - The Netherlands, GATLA - Argentina)

5.30 - 7.00 pm **Poster viewing**

8.30 - 9.40 am

CME

Session XIII - Management of relapse and role of stem cell transplantation

Chairs: **W. Arcese, J. Sierra**

- Which is the best treatment for relapsed APL?
- Arsenic trioxide for the management of relapsed APL patients
- Role of transplantation in APL

E. Lengfelder

M. Breccia

J. Sanz Caballer

CO032

PROLONGED ATO AND ATRA THERAPY FOR RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA

Cicconi L., Breccia M., Franceschini L., Latagliata R., Molica M., Rizzo M., Divona M., Iaccarino L., Ottone T., Alfonso V., Voso M.T., Lo Coco F. (Rome - Italy)

9.40 - 10.40 am

CME

Session XIV - APL as a second tumor and t-MN after APL

Chairs: **G. Leone, P. Montesinos**

- Is APL occurring as a second malignancy different from de novo APL?
- Mitoxantrone related t-APL

R.A. Larson

S.K. Hasan

CO033 CHARACTERISTICS AND OUTCOME OF PATIENTS WITH THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA FRONT-LINE TREATED WITH OR WITHOUT ARSENIC TRIOXIDE-AN INTERNATIONAL COLLABORATION STUDY

Kayser S., Krzykalla J., Elliott M.A., Norsworthy K., Gonzales P., Hills R.K., Baer M.R., Ráčil Z., Mayer J., Novak J., Žák P., Szotkowski T., Grimwade D., Russell N.H., Walter R.B., Estey E.H., Westermann J., Görner M., Benner A., Krämer A., Smith B.D., Burnett A.K., Thiede C., Röllig C., Ho A.D., Ehninger G., Schlenk R.F., Tallman M.S., Levis M.J., Platzbecker U. (Heidelberg, Berlin, Bielefeld, Dresden - Germany, Rochester, Baltimore, New York, Seattle - USA, Cardiff, London, Nottingham - United Kingdom, Brno, Prague, Hradec Králové, Olomouc - Czech Republic)

CO034 MUTATIONAL ANALYSIS OF MDS AND AML OCCURRING AFTER TREATMENT FOR ACUTE PROMYELOCYTIC LEUKEMIA (APL). A REPORT OF 9 CASES

Attias P., Renneville A., Thomas X., Bally C., Hayette S., Farhat H., Eclache V., Marceau A., Cassinat B., Feuillard J., Terré C., Delabesse E., Park S., Lejeune J., Chevret S., Ades L., Preudhomme C., Fenaux P. (Lyon, Versailles, Lille, Paris, Limoges, Toulouse, Grenoble - France, Groupe Français des myélodysplasies - GFM)

10.40 - 11.00 am *Coffee break*

11.00 - 11.40 am **Session XV - Quality of life and health economics**

CME

Chairs: **M. Breccia, M.A. Sanz**

- Short and long-term quality of life outcomes in patients with acute promyelocytic leukemia

F. Efficace

CO035 THE REAL WORLD OF ARSENIC USES IN CHINESE WITH ACUTE PROMYELOCYTIC LEUKEMIA: A CROSS-SECTIONAL SURVEY

Zhu H.H., Zheng F.M. (Beijing - China)

CO036 AVAILABILITY OF ATRA, BLOOD BANK SUPPORT, TREATMENT PROTOCOLS AND HEMATOLOGISTS/ONCOLOGISTS FOR MANAGEMENT OF APL IN TWO STATES (MICHIGAN AND LOUISIANA) IN THE USA

Bolds S., Patel S., Caprara C., DeBragga S., Simon K., Karkhanis P., Arellano M., Jillella A., Kota V. (Atlanta - USA)

11.40 - 12.10 am **Oral Session V - Management of APL in developing countries**

CME

Chairs: **F. Lo Coco, V. Mathews**

CO037 RETROSPECTIVE ANALYSIS OF EARLY MORTALITY IN A COHORT OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Maia T., Chorão P., Aguiar E., Bergantim R., Gomes P., Trigo F. (Porto - Portugal)

CO038 A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENTS ACUTE MYELOID LEUKEMIA: HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA

Farah R., Horkos J., Bustros Y., Farhat H., Abla O. (Beirut - Lebanon, Toronto - Canada)

CO039 EARLY DEATH RATE IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE COMMUNITY CENTRE EXPERIENCE IN SOUTH INDIA

Reddy K., Anupma M., Sitalata C., Kaylan K. (Vijayawada - India)

12.10 - 12.30 pm **Closing remarks**

*F. Lo Coco
M.A. Sanz*

POSTER

01. APL Biology

PO000

MUTATIONAL PROFILE OF RELAPSE-RISK GROUPS IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

Prieto-Conde M.I., Alcoceba M., Sarasquete M.E., Hernández-Ruano M., Jiménez C., García-Álvarez M., Balanzategui A., Corral R., Marín L., Ramos F., Godoy A., Báez A., Gutiérrez N.C., García-Sanz R., González-Díaz M., Chillón M.C. (Salamanca, León, Zaragoza, Ávila - Spain)

PO001

THE SIGNIFICANCE OF ARSENIC INDUCED PML PROTEIN SOLUBILITY CHANGE

Maimaitiying Y., Hao R., Wang C., Chen Y., Naranmandura H. (Hohhot, Hangzhou - China)

PO002

DEVELOPMENT OF A COMBINATION STRATEGY BASED ON ER AND OXIDATIVE STRESS IN ACUTE MYELOID LEUKEMIA

Capuano E., Masciarelli S., Ottone T., Divona M., De Panfilis S., Noguera N.I., Lo Coco F., Fazi F. (Rome - Italy)

PO003

CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF ACUTE MYELOID LEUKEMIA WITH UNCOMMON RARA FUSION VARIANTS

Cicconi L., Montesinos P., Rego E., Schwarzer A., Estey E., Testi AM, Esteve J, Avvisati G, Annibali O, Scardocci A, Castelli R, Lazarevich V, Locatelli F, Kumar J, Sanz MA, Lo Coco F., Ablá O. (Rome, Milan - Italy, Valencia, Barcelona – Spain, San Paulo, Ribeirão Preto - Brazil, Melbourne - Australia, Seattle - USA, Lund - Sweden, Kolkata - India, Toronto - Canada)

PO004

STROMAL-CELLS DOWNREGULATE MIR-23A LEVELS IN LEUKEMIC CELLS TO ACTIVATE PROTECTIVE-AUTOPHAGY AGAINST ARSENIC TRIOXIDE IN ACUTE PROMYELOCYTIC LEUKAEMIA

Ganesan S., Palani H.K., Lakshmanan V., Balasundaram N., Alex A.A., David S., Vyas N., Palakodeti D., Mathews V. (Vellore, Bengaluru - India)

PO005

METHYLATED ARSENIC METABOLITES BIND TO PML PROTEIN BUT DO NOT INDUCE CELLULAR DIFFERENTIATION AND PML-RARA PROTEIN DEGRADATION

Naranmandura H., Islam K., Yang C. (Hangzhou - China)

PO006

FUNCTIONAL GENOMICS BASED APPROACHES FOR DISCOVERY OF NEW MECHANISMS IN ACUTE PROMYELOCYTIC LEUKEMIA

Jalili M., Salehzadeh-Yazdi A., Mohammadi S., Yaghmaie M., Ghavamzadeh A., Alimoghaddam K. (Tehran - Iran, Rostock - Germany)

PO007

THE CANCER-ASSOCIATED HISTONE H3.3 K27M MUTATION BLOCKS CELLULAR SENESCENCE AND IMPAIRS DIFFERENTIATION OF MOUSE HEMATOPOIETIC CELLS

Korf K., Haschke A., Müller J., Puller A.C., Siekmann I., Sternsdorf T. (Hamburg - Germany)

PO008

MISLEADING ACUTE PROMYELOCYTIC LEUKEMIA MORPHOLOGY AND IMMUNOPHENOTYPING: FIVE CASE REPORTS AND LITERATURE REVIEW

Faglioni L., Maceroni D., Anaclerico B., Bongarzone V., Bruno R., Chierichini A., Piccioni A.L., Anticoli Borza P., Cedrone M., Crescenzi Leonetti S., Cortese S., Pauselli F., Tozzi C., Divona M.D., Nervi C., Diverio D., Annino L., Bagnato A., Fenu S. (Rome - Italy)

PO009

TRIB3 PROMOTES APL PROGRESSION THROUGH STABILIZATION OF THE ONCOPROTEIN PML/RARA AND INHIBITION OF P53-MEDIATED SENESENCE

Li K., Wang F., Hua F., Hu Z.W. (Beijing - China)

PO010

PML NUCLEAR BODY DISRUPTION COOPERATES IN APL PATHOGENESIS, IMPACTING DNA DAMAGE REPAIR PATHWAYS

Voisset E., Moravcsik E., Stratford E.W., Jaye A., Palgrave C., Hills R.K., Salomoni P., Kogan S.C., Solomon E., Grimwade D. (London, Guildford, Cardiff - United Kingdom, Oslo - Norway, San Francisco - USA)

PO011

HYPERTRIGLYCERIDEMIA IN NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA

Zhu H.H., Wang W.H., Jia J.S. (Beijing - China)

02. Pathogenesis and management of coagulopathy

PO012

MULTIDISCIPLINARY MANAGEMENT OF SEVERE ACUTE LIMB ISCHEMIA IN A PATIENT WITH ACUTE PROMYELOCYTIC LEUKAEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE

Basilico C., Bianchi B., Ferrario A., Passamonti F. (Varese - Italy)

PO013

ACUTE PROMYELOCYTIC LEUKEMIA CELLS UNDERGO ETOSIS TO EXACERBATE COAGULATION DISORDER

Cao M., Li T., Yang X., Zhou J., Shi J. (Harbin - China, Boston - USA)

PO014

UTILITY OF D-DIMER LEVEL AS A MARKER FOR DIFFERENTIATION SYNDROME, INFECTION, AND DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)

Caprara C., Karkhanis P., Simon K., DeBragga S., Bolds S., Arellano M., Jillella A., Kota V. (Atlanta - USA)

PO015

CEREBROVASCULAR INFARCTS IN THE SETTING OF DISSEMINATED INTRAVASCULAR COAGULATION AS PRESENTING SYMPTOM IN ACUTE PROMYELOCYTIC LEUKEMIA

Simon K., Caprara C., Karkhanis P., DeBragga S., Bolds S., Alghsoon S., Arellano M., Kota V., Jillella A. (Atlanta - USA)

PO016

A NORMAL PROTHROMBIN TIME, ACTIVATED PARTIAL THROMBOPLASTIN TIME AND FIBRINOGEN LEVEL DO NOT ELIMINATE DISSEMINATED INTRAVASCULAR COAGULATION AND BLEEDING RISK IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Simon K., Karkhanis P., Caprara C., DeBragga S., Bolds S., Alghsoon S., Arellano M., Kota V., Jillella A. (Atlanta - USA)

03. Early death and real life data

PO017

DECREASING INDUCTION MORTALITY IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENTS BELONGING TO THE JEHOVAH'S WITNESS CONGREGATION

Caprara C., DeBragga S., Simon K., Bolds S., Karkhanis P., Arellano M., Kota V., Jillella A. (Atlanta - USA)

PO018

COMORBID CONDITIONS IN NEWLY DIAGNOSED PATIENTS WITH APL IN GEORGIA, SOUTH CAROLINA AND NEIGHBORING STATES IN THE USA, DECREASED INDUCTION MORTALITY DESPITE A HIGH COMORBID INDEX

DeBragga S., Simon K., Caprara C., Karkhanis P., Bolds S., Arellano M., Kota V., Jillella A. (Atlanta - USA)

PO019

FOLLOW-UP AND OUTCOME OF TWELVE-YEAR EXPERIENCE IN ADULTS PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Durigon G.S., Moraes A.C., Bigolin A., Rudolf R.C.O., Del Moral J.A.G., Santos-Silva M.C. (Florianópolis - Brazil)

PO020

DECREASING EARLY DEATHS (ED) IN APL IN THE "REAL WORLD". THE GEORGIA AND SOUTH CAROLINA (USA) EXPERIENCE

Jillella A., Arellano M., Karkhanis P., Bolds S., Caprara C., Simon K., Debragga S., Gaddh M., Bernal-Mizrachi L., Heffner L., Winton E., McLemore M., Bodo I., Langston A., Al-Kadhimi Z., Bashey A., Stuart R., Pati A., Gerber J., Grunwald M., Bradley K., Tongol J., El-Geneydy M., Khoury H., Kota V. (Atlanta, Charleston, Spartanburg, Charlotte, Albany - USA)

PO021

RENAL COMPLICATIONS DURING ACUTE PROMYELOCYTIC LEUKEMIA (APL) INDUCTION

Karkhanis P., Bolds S., DeBragga S., Caprara C., Simon K., Jillella A., Arellano M., Kota V. (Atlanta - USA)

PO022

WEIGHT GAIN DURING INDUCTION THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS COULD LEAD TO MAJOR MORBIDITY AND MORTALITY: A PREVENTABLE PROBLEM

Kota V., Caprara C., Karkhanis P., Bolds S., Simon K., Debragga S., Sharma R., Mody A., Arellano M., Jillella A. (Atlanta - USA)

PO023

CHRONIC MYELOID LEUKEMIA IN CHILDHOOD: CLINICAL FEATURES AND THERAPEUTIC STRATEGIES BEFORE TYROSINE KINASE INHIBITOR. A SUCCESSFUL MEDICAL HISTORY

Mariani S., Testi A., Moleti M., Putti M., Micalizzi C., Fagioli F., Favre C., Specchia G., Santoro N., Di Bartolomeo P., Giona F. (Rome, Padua, Genoa, Turin, Florence, Bari, Pescara - Italy)

PO024

HERPES ZOSTER REACTIVATION IN A PATIENT WITH INTERMEDIATE RISK ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE AND ALL-TRANS RETINOIC ACID

Nolte F., Hofmann W.K., Lengfelder E. (Mannheim - Germany)

PO025

A UNIQUE PRESENTATION OF DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA AS A MYELOID SARCOMA OF THE BREAST

Oravcova I., Mikuskova E., Leitnerova M., Copakova L., Gyarfas J., Mlcakova A., Szepe P., Plank L., Demitrovicova L., Mikudova V., Cingelova S., Drgona L. (Bratislava, Martin - Slovakia)

PO026

ACUTE PROMYELOCYTIC LEUKEMIA IN THE THIRD TRIMESTER OF PREGNANCY: TWO DIFFERENT APPROACHES

Solé M., Pérez O., Gil E., Palma A.J., Zapata R., Pérez-Simón J.A., Rodríguez J.N., González-Campos J. (Huelva, Sevilla - Spain)

PO027

DIFFERENCE IN CAUSES AND PROGNOSTIC FACTORS FOR EARLY DEATH BETWEEN COHORTS WITH DE NOVO AND RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA

Zhang Y., Hou J., Zhao H., Zhao Y., Cao F., Li H., Ge F., Hou W., Fu J., Wang P., Sun J., Zhou J. (Harbin – China)

04. Front line therapy of APL

PO028

CLINICAL IMPACT OF BAALC EXPRESSION IN HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA

Lucena-Araujo A.R., Pereira-Martins D.A., Koury L.C., Franca-Neto P.L., Coelho-Silva J.L., M de Deus Wagatsuma V., Melo R.A., Bittencourt R., Pagnano K., Pasquini R., Chiattonne C.S., Fagundes E.M., Chauffaille M.L., Schrier S.L., Tallman M.S., Ribeiro R.C., Grimwade D., Ganser A., Löwenberg B., Lo Coco F., Sanz M.A., Berliner N., Rego E.M. (Recife, San Paulo, Porto Alegre, Campinas, Curitiba - Brazil, Stanford, New York, Boston - USA, London - United Kingdom, Hannover - Germany, Rotterdam - The Netherlands, Rome - Italy, Valencia, Madrid - Spain)

PO029

REDUCTION OF HOSPITALIZATION AND TRANSFUSIONAL SUPPORT WITH FIRST LINE ARSENIC TRIOXIDE IN COMBINATION WITH ALL-TRANS RETINOIC ACID COMPARED TO CHEMOTHERAPY IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: MONOCENTRIC EXPERIENCE

Autore F., Chiusolo P., Sorà F., Giammarco S., Laurenti L., Innocenti I., Metafuni E., Pagano L., Bacigalupo A., Sica S. (Milan - Italy)

PO030

OLDER METHODS AND (NEW) DRUGS: A CASE REPORT OF ACUTE PROMYELOCYTIC LEUKEMIA

Di Prinzio G., Jacqmin H., Mignon V., Sabor L., Sonnet A., Chatelain B. (Godinne, Louvain – Belgium)

PO031

APL IN OBESE: SHOULD WE TREAT IT DIFFERENTLY?

Jitani A.K., Chakrabarti P., Dolai T.K., Dutta S., De R., Mandal P.K. (Kolkata – India)

PO032

IS ARSENIC TRIOXIDE (ATO) REQUIRED IN THE TREATMENT OF HIGH RISK NEWLY DIAGNOSED APL? ANALYSIS OF A RANDOMIZED TRIAL (APL2006) BY THE FRENCH BELGIAN SWISS APL GROUP

Ades L., Raffoux E., Spertini O., Guerci A., Recher C., Guyotat D., Deconinck E., De La Chapelle T.L., Thomas X., Bordessoule D., Vey N., de Botton S., Pigneux A., Caillot D., Cahn J.Y., Chevallier P., Lambert J.F., Gardin C., Dombret H., Lejeune J., Chevret S., Fenaux P. (French Belgian Swiss APL Group)

PO033

IS ARSENIC TRIOXIDE (ATO) REQUIRED IN THE TREATMENT OF STANDARD RISK NEWLY DIAGNOSED APL? ANALYSIS OF A RANDOMIZED TRIAL (APL 2006) BY THE FRENCH BELGIAN SWISS APL GROUP

Ades L., Thomas X., Guerci-Bresler A., Raffoux E., Spertini O., Vey N., Lamy T., Récher C., Pigneux A., Bordessoule D., Deconinck E., Gardin C., Tournilhac O., Lambert J.F., Chevallier P., De Botton S., Lejeune J., Dombret H., Chevret S., Fenaux P. (French Belgian Swiss APL Group)

PO034

DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA: A MONO CENTRIC STUDY

Merrouche M., Aiche M., Refis S., Soltani F., Kacha F., Nacib R., Hariz A., Zeroual N., Rechache H., Belaid D., Gareh B., Temlali M., Dridi R., Bouaziz S., Bekache A., Saidi M. (Batna - Algeria)

PO035

THE KINETICS OF WHITE BLOOD CELL AND PREDICTIVE FACTORS OF LEUKOCYTOSIS UNDER THE ORAL ARSENIC OR INTRAVENOUS ARSENIC AS FIRST-LINE TREATMENT FOR ACUTE PROMYELOCYTIC LEUKEMIA

Zhu H.H., Wang .F, Jia J.S., Huang X.J. (Beijing – China)

PO036

CHARACTERISTICS AND CLINICAL OUTCOME OF APL PATIENTS FROM THREE DIFFERENT COUNTRIES TREATED WITH THE PETHEMA LPA2005 PROTOCOL

Sobas M., Holowiecka A., Paluszewska M., Podhorecka M., Pluta A., Piatkowska-Jakubas B., Zijlmans J.M., Jongen-Lavrencic M., Ossenkoppele G., Lowenberg B., Vellenga E., De la Serna J., Amutio E., Krsnik I., Bergua J., Gil C., Serrano J., Montesinos P., Sanz M.A. (PETHEMA - Spain, PALG - Poland, HOVON - The Netherlands, GATLA - Argentina)

05. APL in children and elderly patients**PO037**

EXPERIENCE WITH ATO AND ATRA TREATMENT IN PEDIATRIC PATIENTS WITH LOW RISK APL

Creutzig U., Dworzak M.N., Bochenek K., Faber J., Flotho J., Graf N., Kontny U., Rossig C., Schmid I., von Stackelberg A., Mueller J.E., von Neuhoff C., Reinhardt D., von Neuhoff N. (Vienna - Austria, Hannover, Frankfurt, Mainz, Freiburg, Saarbrücken, Aachen, Muenster, Munich, Berlin, Essen - Germany)

PO038

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 YEARS: REAL-LIFE RESULTS

De Luca M.L., Latagliata R., Breccia M., Minotti C., Carmosino I., Molica M., Cesini L., De Benedittis D., Chisini M., Scalzulli E., Loglisci M.G., Vozella F., Cartoni C., Diverio D., Foà R. (Rome - Italy)

PO039

RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE IN A VERY ELDERLY PATIENT WITH SERIOUS COMORBIDITIES

Merchionne F., Romano A., Mele G., Coppi M.R., Melpignano A. (Brindisi - Italy)

PO040

EXPERIENCE OF THE ARGENTINIAN GROUP OF TREATMENT OF ACUTE LEUKEMIA (GATLA) IN PEDIATRIC ACUTE PROMIELOCYTIC LEUKEMIA (APL)

Freigeiro D., Moran L., Deana A., Cedola A., Reichel P., Zirone S., Elena G., Felice M., Arrieta M.E., Arbezú G., Alonso C., Fynn A. (Buenos Aires, Neuquen, Santiago de Estero, Rosario, Mendoza, San Juan, Ciudad de La Plata - Argentina)

PO041

ARSENIC TRIOXIDE (ATO) AND ALL-TRANS RETINOIC ACID (ATRA) FOR TREATMENT OF PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA

Gurnari C., Strocchio L., Vinti L., Putti M.C., Zecca M., Menna G., Merli P., Gaspari S., Girardi K., Basso G., Testi A.M., Lo Coco F., Locatelli F. (Rome, Padua, Pavia, Naples - Italy)

PO042

OUTCOMES IN ELDERLY APL PATIENTS: A PERSONALIZED TREATMENT APPROACH ALONG WITH EXPERT SUPPORT MIGHT REDUCE EARLY DEATHS

Kota V., Arellano M., Karkhanis P., Bolds S., Caprara C., Simon K., Debragga S., Gaddh M., Bernal-Mizrachi L., Heffner L., Winton E., McLemore M., Bodo I., Langston A., Al-Kadhimi Z., Bashey A., Stuart R., Pati A., Gerber J., Grunwald M., Bradley K., Tongol J., El-Geneidy M., Houry J., Jillella A. (Atlanta, Charleston, Spartanburg, Charlotte, Albany, Columbia - USA)

PO043

VERY ELDERLY ACUTE PROMYELOCYTIC LEUKEMIA: A MULTICENTRIC EXPERIENCE

Salamero O., Martínez-Cuadrón D., Gallur L., Vellenega E., Bernal T., Holowiecka A., Brunet S., Gil C., Benavente C., Ribera J.M., Pérez-Encinas M., De la Serna J., Esteve J., Rubio V., González-Campos J., Escoda L., Amutio M.E., Arnan M., Arias J., Negri S., Sanz M.A., Montesinos P. (Barcelona, Valencia, Asturias, Oviedo, Badalona, Jerez de la Frontera, Bizkaia, Hospitalet de Llobregat, Alicante, Madrid, Santiago de Compostela, Sevilla, Tarragona, Lugo, Málaga - Spain, Katowice - Poland, Groningen - The Netherlands)

PO044

APL IN THE ELDERLY: EFFICIENT CONSOLIDATION THERAPY USING THE SHORT "MATTHEWS" COURSES OF ARSENIC AND ATRA

Schwarz J., Marková J., Šálek C., Soukup P. (Prague - Czech Republic)

PO045

TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS AGED OVER 60 YEARS- EXPERIENCE FROM A HUNGARIAN CENTER

Tárkányi I., Mucsi O., Körösmezey G., Gaál-Weisinger J., Csomor J., Nagy Z.S., Demeter J. (Budapest - Hungary)

06. Treatment of relapse and role of stem cell transplantation**PO046**

ASSESSMENT OF ARSENITE-RESISTANCE MUTANT PML PROTEIN SOLUBILITY CHANGES BY PHENYLARSINE OXIDE

Wang C., Chen Y., Hao R., Maimaitiying Y., Naranmandura H. (Hangzhou - China)

PO047

RELAPSED APL AND ITS TREATMENT OUTCOME – A STUDY FROM EASTERN INDIA

Phukan A., Chakrabarti P., Dolai T.K., De R., Mandal P.K., Baul S. (Kolkata - India)

PO048

ACUTE PROMYELOCYTIC LEUKEMIA RELAPSING AS MYELOID SARCOMA WITH FLUCTUATING MINIMAL RESIDUAL DISEASE LEVELS AND LYMPH NODE INVOLVEMENT: A CASE REPORT

Piccini M., Grieco P., Gianfaldoni G., Scappini B., Mannelli F., Fanci R., Bosi A. (Florence - Italy)

07. APL as a second tumor and t-MN after APL**PO049**

THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA. EXPERIENCE IN A SINGLE INSTITUTION IN ARGENTINA

Alfaro E., Gutter M., Sánchez La Rosa C., Millán N., Baialardo E., Alonso C., Rossi J., Zubizarreta P., Felice M. (Buenos Aires - Argentina)

PO050

LONG-TERM FOLLOW-UP OF FIRST LINE ARSENIC TRIOXIDE IN COMBINATION WITH ALL-TRANS RETINOIC ACID COMPARED TO CHEMOTHERAPY IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: MONOCENTRIC EXPERIENCE

Autore F., Chiusolo P., Sorà F., Giammarco S., Laurenti L., Innocenti I., Metafuni E., Pagano L., Bacigalupo A., Sica S. (Rome - Italy)

POSTER

PO051

THERAPY-RELATED AML WITH DIC(5,17) FOLLOWING TREATMENT FOR APL WITH T(15,17): TWO INDEPENDENT MYELOID MALIGNANCIES INVOLVING CHROMOSOME 17 TRANSLOCATIONS

Hackett C., Gupta M., Dunbar A., Tallman M. (New York - USA)

PO052

SECONDARY MALIGNANCY AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA: A REPORT BY THE RETE EMATOLOGICA PUGLIESE (REP)

Melillo L., La Torre A., Carluccio P., Buquicchio C., Giannotta A., Spinosa G., Capalbo S., Di Renzo N., Melpignano A., Pavone V., Tarantini G., Specchia G., Cascavilla N. (San Giovanni Rotondo, Bari, Barletta, Brindisi, Foggia, Lecce, Tricase - Italy)

PO053

THERAPY-RELATED MYELODYSPLASTIC SYNDROME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH ACUTE PROMYELOCYTIC LEUKEMIA IN SECOND REMISSION – A CASE REPORT

Ostojic A., Roncevic P., Basic-Kinda S., Sertic D. (Zagreb - Croatia)

GENERAL INFORMATION

MEETING VENUE

NH Hotel Vittorio Veneto
Corso d'Italia, 1 - 00198 Roma
Phone +39 06 84951

LANGUAGE

The meeting will be in English with no simultaneous translation.

ITALIAN CME CREDITS

A request for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-197747.
- No. 6 CME credits for physicians (disciplines: Clinical Biochemistry, Hematology, Oncology, Internal Medicine, Clinical Pathology, Microbiology and Virology) technicians and biologists.
- Educational objective: "guidelines-protocols-procedures".

EUROPEAN CME CREDITS

The program of the "7TH INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 21 CME credits for physicians, technicians and biologists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org> even on site.

BADGE

All registered participants and speakers will be given a badge which they must wear to be admitted to the scientific sessions.

GENERAL INFORMATION

ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the meeting.

SLIDES

Slides must be in English. Computer videoprojection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible. Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

CHANGES

Parts of the program may be changed if necessary.

REGISTRATION FEES

(Italian VAT included)

Euro 450,00

Euro 250,00 under 30 years old

Euro 200,00 accepted abstracts' submitters

The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, welcome cocktail, coffee breaks, lunches.

HOTEL BOOKING

Studio E.R. Congressi

Via Marconi, 36 - 40122 Bologna, Italy

Phone +39 051 4210559

Fax +39 051 4210174

E-mail: ercongressi@ercongressi.it

www.ercongressi.it

ACKNOWLEDGEMENTS





SCIENTIFIC SECRETARIAT

Massimo Breccia
Claudia Carissimo
Laura Cicconi
Serena Lavorogna
Maria Teresa Voso
E-mail: segr.apl2017@gmail.com

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Tel. +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

www.apl2017.com